Mineralys Therapeutics (NASDAQ:MLYS) Shares Climb 4.4% - What's Next?

Mineralys Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Mineralys shares rose 4.4% to $14.38, although trading volume was 59% below its average.
  • Analysts’ consensus rating is Hold, with an average price target of $43.60; individual ratings range from strong sell to buy.
  • The company reported a quarterly loss of $0.64 per share, missing the $0.55 loss expected by analysts. Insiders have sold 197,195 shares worth about $5.4 million over the past 90 days.
  • Interested in Mineralys Therapeutics? Here are five stocks we like better.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report)'s stock price shot up 4.4% on Thursday. The stock traded as high as $14.71 and last traded at $14.3810. Approximately 552,901 shares traded hands during trading, a decline of 59% from the average daily volume of 1,350,053 shares. The stock had previously closed at $13.78.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on MLYS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Thursday, October 15th. UBS Group assumed coverage on shares of Mineralys Therapeutics in a research note on Sunday, October 11th. They set a "neutral" rating and a $29.00 price objective on the stock. Wall Street Zen downgraded Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Zacks Research upgraded Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Friday, September 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $56.00 price objective on shares of Mineralys Therapeutics in a research note on Monday, October 12th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $43.60.

View Our Latest Report on Mineralys Therapeutics

Mineralys Therapeutics Stock Performance

The company's 50 day simple moving average is $21.72 and its 200 day simple moving average is $25.92. The stock has a market cap of $1.25 billion, a PE ratio of -3.29 and a beta of 0.83. The company has a debt-to-equity ratio of 0.15, a quick ratio of 11.83 and a current ratio of 11.83.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.09). Analysts expect that Mineralys Therapeutics, Inc. will post -4.64 earnings per share for the current year.

Insider Buying and Selling at Mineralys Therapeutics

In other news, Director Brian Slingsby sold 104,320 shares of the firm's stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $28.81, for a total value of $3,005,459.20. Following the completion of the transaction, the director directly owned 7,805,718 shares of the company's stock, valued at $224,882,735.58. This trade represents a 1.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daphne Karydas sold 3,000 shares of the business's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $28.58, for a total value of $85,740.00. Following the sale, the director owned 6,200 shares in the company, valued at approximately $177,196. The trade was a 32.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 197,195 shares of company stock valued at $5,403,069. 18.94% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of large investors have recently modified their holdings of the company. Algert Global LLC boosted its position in shares of Mineralys Therapeutics by 28.5% during the 3rd quarter. Algert Global LLC now owns 834,309 shares of the company's stock valued at $20,966,000 after acquiring an additional 185,282 shares during the last quarter. Virtu Financial LLC increased its holdings in shares of Mineralys Therapeutics by 81.4% in the 3rd quarter. Virtu Financial LLC now owns 16,116 shares of the company's stock worth $405,000 after buying an additional 7,230 shares during the last quarter. Bellevue Group AG raised its position in shares of Mineralys Therapeutics by 32.3% during the 3rd quarter. Bellevue Group AG now owns 11,576 shares of the company's stock valued at $291,000 after buying an additional 2,823 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Mineralys Therapeutics during the 3rd quarter valued at $1,961,000. Finally, Marshall Wace LLP lifted its holdings in shares of Mineralys Therapeutics by 43.3% during the 3rd quarter. Marshall Wace LLP now owns 25,800 shares of the company's stock worth $648,000 after acquiring an additional 7,800 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors.

About Mineralys Therapeutics

(Get Free Report)

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019. Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Mineralys Therapeutics Right Now?

Before you consider Mineralys Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.

While Mineralys Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines